The content on this site is intended for healthcare professionals only
Prof Underwood speaks with ecancertv at NCRI 2016 about steps towards personalised therapy availability of oesophageal cancer.
The UK has a high incidence of oesophageal cancer, though no one obvious cause in environmental has been indicated as the lead culprit.
Prof Underwood summarises the sessions presentations on establishing mutational subtypes of oesophageal adenocarcinoma and modelling Barretts Oesophagus, with an eye towards future therapies with targeted immunotherapy.
Transforming cancer care in India: The Access Cancer Care Initiative
ESMO 2024: Optimising the personalisation of prostate cancer treatment
GIST tumours and soft tissue sarcomas
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 4th - 10th, 2023
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
